MARKET

SPPI

SPPI

Spectrum Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.680
+0.005
+0.00%
After Hours: 3.670 -0.01 -0.27% 17:45 08/12 EDT
OPEN
3.710
PREV CLOSE
3.680
HIGH
3.770
LOW
3.550
VOLUME
2.37M
TURNOVER
--
52 WEEK HIGH
10.57
52 WEEK LOW
1.742
MARKET CAP
514.06M
P/E (TTM)
-3.0065
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SPPI stock price target is 10.75 with a high estimate of 15.00 and a low estimate of 7.00.

EPS

SPPI News

More
Spectrum Pharmaceuticals Inc (SPPI) Q2 2020 Earnings Call Transcript
Thank you for joining us today for Spectrum Pharmaceuticals' second quarter 2020 financial results conference call. Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO; Dr. Francois Lebel, Chief Medical Officer; a
Motley Fool · 1d ago
Spectrum Pharmaceuticals (SPPI) Reports Q2 Loss, Lags Revenue Estimates
Spectrum Pharma (SPPI) delivered earnings and revenue surprises of 12.12% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 2d ago
Spectrum Pharmaceuticals Q2 EPS $(0.28) Beats $(0.32) Estimate
Spectrum Pharmaceuticals (NASDAQ:SPPI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.32) by 12.5 percent. This is a 21.74 percent decrease over losses of $(0.23) per
Benzinga · 2d ago
Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update
Spectrum Pharmaceuticals Reports Second Quarter 2020 Financial Results and Corporate Update
Business Wire · 2d ago
Spectrum Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Spectrum Pharmaceuticals Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
Business Wire · 08/05 20:00
Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Spectrum Pharmaceuticals to Report Second Quarter 2020 Financial Results and Provide Corporate Update
Business Wire · 08/03 11:00
BLNK, PEIX, GTX and BEP among midday movers
Seeking Alpha · 07/30 16:42
Healthcare - Top 5 Gainers / Losers
Seeking Alpha · 07/30 15:04

Industry

Biotechnology & Medical Research
+0.70%
Pharmaceuticals & Medical Research
+1.61%

Hot Stocks

Symbol
Price
%Change

About SPPI

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company operates through developing and commercializing oncology and hematology drug products segment. It focuses on developing ROLONTIS and POZIOTINIB. ROLONTIS is being investigated for the treatment of chemotherapy-induced neutropenia. POZIOTINIB is an oral pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR, HER) Family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.
More

Webull offers kinds of Spectrum Pharmaceuticals, Inc. stock information, including NASDAQ:SPPI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPPI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPPI stock methods without spending real money on the virtual paper trading platform.